Profil
Ken Keyong Ren is the founder of AHT, Inc., ImmunoVentis, Inc., China Innovation Center for Life Science, and Novemed, Inc. He was the President of Accelovance China from 2005 to 2012.
Prior to that, he worked as a Research Scientist at Pfizer Inc. from 1993 to 1995.
He also served as the Chief Investment Director at CCBI Healthcare Fund.
Dr. Ren holds a doctorate degree from the State University of New York at Buffalo, which he received in 1990, and another doctorate degree from Shandong Medical University, which he received in 1986.
Anciens postes connus de Ken Keyong Ren
| Sociétés | Poste | Fin |
|---|---|---|
CASI Pharmaceuticals, Inc. /Old/
 CASI Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs. The company develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong, and Macau. Its products include Zevalin, Evomela, and Marqibo. The company was founded in 1991 and is headquartered in Rockville, MD. | Chief Executive Officer | 02/04/2019 |
| Accelovance China | President | 01/01/2012 |
| PFIZER, INC. | Corporate Officer/Principal | 01/01/1995 |
| Novemed, Inc. | Chief Executive Officer | - |
| CCBI Healthcare Fund | Chief Investment Officer | - |
Formation de Ken Keyong Ren
| State University of New York at Buffalo | Doctorate Degree |
| Shandong Medical University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PFIZER, INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
CASI Pharmaceuticals, Inc. /Old/
CASI Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs. The company develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong, and Macau. Its products include Zevalin, Evomela, and Marqibo. The company was founded in 1991 and is headquartered in Rockville, MD. | Health Technology |
ImmunoVentis, Inc.
 ImmunoVentis, Inc. BiotechnologyHealth Technology ImmunoVentis, Inc. manufactures immunotherapy vaccines and products. It offers immunomodulation and immunotherapy through interfering with cytokine signaling suppressors. The company was founded on July 21, 2008 and is headquartered in Beijing, China. | Health Technology |
| AHT, Inc. | |
| China Innovation Center for Life Science | |
| CCBI Healthcare Fund | |
| Accelovance China | |
| Novemed, Inc. |
